1 / 16

Optimizing Treatment of Relapsing-Remitting MS

General Issues. Current DMD's are not curativeMost patients in the trials eventually experienced outcomes (i.e. relapse, progression or MRI activity)With no placebo comparative group, how can you know if a patient is doing better" than expected?. Annualized Relapse Rate Regression* in Pivotal Tri

ahava
Télécharger la présentation

Optimizing Treatment of Relapsing-Remitting MS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. Optimizing Treatment of Relapsing-Remitting MS Mark S. Freedman MSc MD FAAN FRCPC Professor of Neurology University of Ottawa Ottawa, Ontario CANADA

More Related